Calliditas Therapeutics AB - ADR

+0.11 (+0.60%)
5:02:37 PM EDT: $18.50 -0.04 (-0.22%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)497.55M
Current PEN/A
Forward PE N/A
2yr Forward PE 6.33
See more stats
Estimates Current Quarter
Revenue$29.89 Million
Adjusted EPS-$0.13
See more estimates
10-Day MA$17.36
50-Day MA$17.38
200-Day MA$19.36
See more pivots

Calliditas Therapeutics AB - ADR Stock, NASDAQ:CALT

D5, Kungsbron 1, Stockholm, Stockholm 111 22
Phone: +46.8.411.3005
Number of Employees: 178


Calliditas Therapeutics AB clinical-stage biopharmaceutical company. It engages in the identification, development, and commercialization of novel treatments in orphan indications. The firm focuses on renal and hepatic diseases with significant unmet medical needs. It offers Nefecon, a proprietary, novel oral formulation of budesonide for the treatment of the autoimmune renal disease IgA nephropathy, or IgAN. The firm product TARPEYO is used to reduce proteinuria in adults with primary immunoglobulin. The company was founded by Mikael Bender and Bengt ��ke Julander on February 20, 2004 and is headquartered in Stockholm, Sweden.